mouse monoclonal IgG1; Pmel17 Antibody (E-7) is an IgG1 κ mouse monoclonal Pmel17 antibody (also designated Premelanosome Protein antibody, Melanocytes Lineage-Specific Antigen GP100 antibody, Melanoma-Associated ME20 Antigen antibody, Melanocyte Protein Pmel 17 antibody, Melanocyte Protein PMEL antibody, ME20-M antibody, PMEL17 antibody, ME20M antibody, Gp100 antibody, P100 antibody, SILV antibody, P1 antibody, SI antibody, Silver (Mouse Homolog) Like antibody, or Melanocyte Protein Mel 17 antibody) that detects the Pmel17 protein of human origin by WB, IP, IF and ELISA. Pmel17 Antibody (E-7) is available as both the non-conjugated anti-Pmel17 antibody form, as well as multiple conjugated forms of anti-Pmel17 antibody, including agarose, HRP, PE, FITC and multiple Alexa Fluor® conjugates. Cytotoxic T lymphocytes (CTLs) recognize melanoma-associated antigens, which belong to three main groups. These groups include tumor-associated testis-specific antigens, melanocyte differentiation antigens and mutated or aberrantly expressed antigens, which are routinely used as markers to identify melanomas based on their binding to specific monoclonal antibodies. gp100, also designated ME20-M, ME20-S and PMEL 17, is classified as a melanocyte differentiation antigen and is expressed at low levels in normal cell lines and tissues, but is upregulated in melanocytes. gp100 is a highly glycosylated protein. It is also the product of proteolytic cleavage, which results in a secreted protein. gp100 is recognized by several monoclonal antibodies, including NKI-beteb, HMB-50 and HMB-45, which are used to diagnose melanomas. Therefore, gp100 is considered a potential target for immunotherapy of malignant melanoma.